Catalyst Wire Dossier Catalyst Wire Dossier

NK042

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for NK042, covering 2024-05-16 to 2025-05-29. Get the full timeline:

Most recent: Clinical Trial Update: NK010 or NK042 in Combination With Rituximab for Refractory Systemic Lupus Erythematosus/Lupus Nephritis [Phase 1]

See pricing